A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)
Latest Information Update: 25 Dec 2024
Price :
$35 *
At a glance
- Drugs Batoclimab (Primary)
- Indications Graves ophthalmopathy
- Focus Registrational; Therapeutic Use
- Sponsors Immunovant
- 19 Dec 2024 Planned End Date changed from 1 Jan 2025 to 1 Dec 2025.
- 19 Dec 2024 Planned primary completion date changed from 1 Dec 2024 to 1 Dec 2025.
- 10 Aug 2023 According to an Immunovant media release, top-line data are expected in the first half of calendar year 2025.